dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa]
dihydroergotamine mesylate
RxCUI: 2569842
What the CMS Formulary Data Shows for dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa]
Per the CMS 2026 Part D formulary file, dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] (RxNorm concept RXCUI 2569842, generic name dihydroergotamine mesylate) appears on 1 distinct formulary file spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.
Real-world access to dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,239 Part D beneficiaries filled dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] in 2023, with total plan-and-beneficiary spending of $35,507,528 and an average per-beneficiary annual cost of $10,962.50. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 5, Specialty
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 3,239
- Total spending
- $35,507,528
- Avg per beneficiary
- $10,962.50
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $47.00 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $79.70 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T5 | No | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T5 | No | $112.70 | PA |
Frequently Asked Questions
Is dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] covered by Medicare Part D?
Yes, dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] on Medicare Part D plans?
dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.
Does dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] require prior authorization?
0% of Part D formularies require prior authorization for dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa]?
In 2023, total Medicare Part D spending on dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa] was $35,507,528, covering 3,239 beneficiaries. The average spend per beneficiary was $10,962.50.
Read our methodology - how this data is sourced, computed, and verified.